Tricida, Inc., is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (also known as TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD).
Metabolic acidosis is a chronic condition commonly caused by CKD that is believed to accelerate the progression of CKD, increase the risk of muscle wasting and cause the loss of bone density. Metabolic acidosis is estimated to pose a health risk to approximately three million patients with CKD in the United States and currently there are no U.S. Food and Drug Administration (FDA)-approved chronic therapies for treating metabolic acidosis.
Veverimer was discovered and developed by Tricida. It is designed to potentially treat chronic metabolic acidosis by binding and removing hydrochloric acid within the gastrointestinal tract.
Veverimer is an investigational drug candidate, discovered and developed at Tricida. It is not approved for therapeutic use by any regulatory agency.
Tricida was founded in August 2013 by a seasoned management team that has extensive experience in the development and commercialization of therapeutics, with substantial expertise in developing polymers for the treatment of kidney-related diseases.
Tricida is a publicly traded company whose shares trade on the NASDAQ Global Market. To learn more about Tricida, please visit our website.